Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
FSD Pharma Inc. - Class B Subordinate Voting Shares
(NQ:
HUGE
)
0.0899
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about FSD Pharma Inc. - Class B Subordinate Voting Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
FSD Pharma Inc. Board Approves Share Repurchase Program
December 30, 2021
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The...
Via
Benzinga
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
December 30, 2021
Via
Investor Brand Network
FSD Pharma Announces Share Repurchase Program
December 30, 2021
From
FSD Pharma Inc.
Via
Business Wire
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
December 28, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
FSD Pharma Announces Establishment of Advisory Board, Strategic Appointments
December 23, 2021
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory...
Via
Benzinga
FSD Pharma Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating
December 23, 2021
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data...
Via
Benzinga
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
December 23, 2021
Via
Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
December 23, 2021
Via
Investor Brand Network
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
December 09, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
December 03, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
December 02, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
November 16, 2021
From
FSD Pharma Inc.
Via
Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
October 19, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
September 22, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
September 21, 2021
From
FSD Pharma Inc.
Via
Business Wire
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
August 30, 2021
Contents
Via
Benzinga
Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals
August 25, 2021
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:
Via
Benzinga
FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm
August 25, 2021
FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma...
Via
Benzinga
54 Biggest Movers From Yesterday
August 26, 2021
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently...
Via
Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
August 25, 2021
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR...
Via
Benzinga
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
August 25, 2021
From
FSD Pharma Inc.
Via
Business Wire
See Why FSD Pharma Terminated COVID-19 Trial
August 25, 2021
FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
August 25, 2021
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Exposures
COVID-19
21 Stocks Moving in Wednesday's Pre-Market Session
August 25, 2021
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported...
Via
Benzinga
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
August 24, 2021
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
July 27, 2021
From
FSD Pharma Inc.
Via
Business Wire
64 Biggest Movers From Friday
June 07, 2021
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM...
Via
Benzinga
40 Stocks Moving In Friday's Mid-Day Session
June 04, 2021
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday. Senseonics Holdings, Inc. (NYSE: SENS) gained 26% to $2.5817 after the...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.